GlassScriptPhysician profile
Lori A Ricklefs
NPI 1376864199
$5,080.07
in general payments reported to CMS, 2019-2025
38 companies · $303 in 2025
The $303 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $261 · 2021: $273 · 2022: $1,336 · 2023: $1,420 · 2024: $1,324 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,046.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $847.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $611.08 | 2020-2025 | Farxiga, Airsupra, Fasenra |
| Amgen INC. | $473.56 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $421.72 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $377.19 | 2021-2025 | |
| Pfizer INC. | $249.52 | 2021-2024 | |
| Glaxosmithkline, LLC. | $216.38 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $206.76 | 2020-2024 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.73 | 2021-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $175.91 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.78 | 2021-2025 | Xifaxan, Trulance |
| Hikma Pharmaceuticals USA | $95.45 | 2022 | |
| Idorsia Pharmaceuticals US INC | $87.12 | 2023-2024 | Quviviq |
| Astellas Pharma US INC | $75.69 | 2021-2023 | Veozah |
| Abbott Laboratories | $74.07 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $71.87 | 2023-2024 | Strensiq |
| Amarin Pharma, INC. | $68.27 | 2022 | |
| Eisai INC. | $67.59 | 2021-2024 | |
| Allergan, INC. | $61.34 | 2019-2020 | |
| Exact Sciences Corporation | $53.10 | 2023 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $52.72 | 2021-2023 | Seglentis, Livalo |
| Amneal Pharmaceuticals LLC | $49.33 | 2022-2024 | Unithroid |
| Grifols USA, LLC | $49.30 | 2023 | Prolastin-C Liquid |
| Sanofi Pasteur INC. | $48.61 | 2024-2025 | |
| Esperion Therapeutics, INC. | $42.77 | 2023 | Nexletol |
| Corium, LLC | $36.81 | 2022-2023 | Azstarys |
| C2n Diagnostics, LLC | $27.56 | 2025 | Precivityad2 |
| Sanofi-Aventis U.S. LLC | $26.13 | 2022 | |
| Daiichi Sankyo INC. | $26.11 | 2022 | |
| Corcept Therapeutics | $24.54 | 2025 | Korlym |
| Hologic Sales and Service, LLC | $23.75 | 2024 | Aptima, Thinprep 2000 Processor |
| Shield Therapeutics INC | $17.47 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.78 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.15 | 2023 | Trintellix |
| Phathom Pharmaceuticals, INC. | $14.73 | 2024 | Voquezna |
| Sonex Health, INC. | $13.57 | 2024 | Sx-One Microknife |
| Regeneron Healthcare Solutions, INC. | $13.33 | 2023 | Evkeeza |
| Therapeuticsmd, INC. | $12.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Ricklefs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.